BTMDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
biote Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.08−0.00 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $30.92M
- P/E (TTM)
- 10.8
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
71.5%
Operating margin
18.5%
Net margin
14.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -2.5% | +5.2% | – | – | |
| Gross profit | -1.2% | +7.6% | – | – | |
| Operating income | +12.5% | – | – | – | |
| Net income | +756.7% | – | – | – | |
| EPS, diluted | +722.2% | – | – | – | |
| Free cash flow | -22.2% | – | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -32.9% | |
| Return on assets | – | – | 23.5% | |
| Current ratio | 0.01 | 0.01 | 1.22 | |
| Debt to equity | – | – | -1.74 | |
| Net debt to EBITDA | – | – | 1.99× | |
| Inventory turnover | – | – | 3.2× | |
| Capex to revenue | – | – | 2.6% | |
| Diluted shares | – | – | 37M |
Where the cash went
Fiscal 2021 to 2025, five years combined
biote generated $150.20M from operations and spent $62.00M on capital expenditure, dividends and share buybacks. 22% of that went back into the business.
Generated
$150.20M
Used
$62.00M
Capital expenditure$13.59M22%Dividends$39.45M64%Share buybacks$8.96M14%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin14.1%
×Asset turnover1.67×
×Equity multiplier-1.40×
=Return on equity, FY2025-32.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 14.1% | 1.67× | -1.40× | -32.9% |
| FY2024 | 1.6% | 1.42× | -2.05× | -4.7% |
| FY2023 | 1.8% | 1.39× | -3.61× | -9.0% |
| FY2022 | -0.6% | 1.99× | -4.12× | 4.8% |
| FY2021 | 8.0% | 5.12× | 13.13× | 535.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$27.05M
- Cash generatingOperating cash flow above zero$35.19M
- Return on assets improvedROA up on the prior year2.0% → 22.1%
- Earnings backed by cashOperating cash flow above net income$35.19M vs $27.05M
- Less leverageLong-term debt to assets fell82.7% → 89.0%
- Better liquidityCurrent ratio rose1.32 → 1.22
- No dilutionShare count did not rise34M → 37M
- Gross margin improvedGross margin up on the prior year70.52% → 71.46%
- More efficientAsset turnover rose1.27 → 1.57